SUDHIR SHAH, MD
Osteopathic Medicine at Markham St, Little Rock, AR
License number
Arkansas R-4130
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
4301 W Markham St #783, Little Rock, AR 72205
Phone
(501) 686-8000
Organization information
See more information about SUDHIR SHAH at bizstanding.comSudhir Shah MD,MBBS,BS
4301 W Markham St, Little Rock, AR 72205
Industry:
Internist
Phone:
(501) 257-5832 (Phone)
Sudhir Vithalbhai Shah V
Professional information
Methods Of Treating Humans Undergoing Injection Of A Contrast Agent
US Patent:
2008029, Nov 27, 2008
Filed:
Jan 28, 2008
Appl. No.:
12/010656
Inventors:
Sudhir V. Shah - Little Rock AR, US
Assignee:
Shiva Biomedical, LLC - Paramus NJ
International Classification:
A61K 31/44, A61K 31/164, A61P 13/12
US Classification:
514348, 514616
Abstract:
A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure.
Dr. Sudhir Shah - MD (Doctor of Medicine)
Hospitals:
4301 W Markham St STE 783, Little Rock 72205
4301 W Markham St STE 783, Little Rock 72205
4301 W Markham St STE 783, Little Rock 72205
Education:
Medical Schools
University Of Mumbai
Graduated: 1971
University Of Mumbai
Graduated: 1971
Diagnosing Atherosclerosis Risk By Measuring Carbamylated Low Density Lipoprotein Levels
US Patent:
7476551, Jan 13, 2009
Filed:
Aug 27, 2002
Appl. No.:
10/228493
Inventors:
Yousri M. Barri - Plano TX, US
Sudhir V. Shah - Little Rock AR, US
Alexei G. Basnakian - Little Rock AR, US
Sudhir V. Shah - Little Rock AR, US
Alexei G. Basnakian - Little Rock AR, US
Assignee:
The Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
G01N 33/53
US Classification:
436547, 435 71, 435 792, 435 12, 4352872, 435967, 436548, 436 15, 436 16, 436 74, 436177, 436811
Abstract:
The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.
Prevention And Treatment Of Atherosclerosis By Reducing Carbamylation Of Ldl Or The Effects Of Carbamylated Ldl
US Patent:
7722858, May 25, 2010
Filed:
Feb 9, 2006
Appl. No.:
11/350660
Inventors:
Sudhir V. Shah - Little Rock AR, US
Alexei G. Basnakian - Little Rock AR, US
Yousri M. Barri - Richardson TX, US
Alexei G. Basnakian - Little Rock AR, US
Yousri M. Barri - Richardson TX, US
Assignee:
Board of Trustees of the University of Arkansas - Little Rock AR
The United States of America as represented by the Department of Veterans Affairs - Washington DC
The United States of America as represented by the Department of Veterans Affairs - Washington DC
International Classification:
A61K 49/00
US Classification:
424 92, 424 934, 435 2, 435 3, 435967, 436 15, 436 16, 436 55, 436 71, 436175, 436177, 436178, 436506, 436811
Abstract:
The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.
Methods Of Treating Erythropoietin-Resistance
US Patent:
2006012, Jun 15, 2006
Filed:
Nov 10, 2005
Appl. No.:
11/271497
Inventors:
Sudhir Shah - Little Rock AR, US
International Classification:
A61K 31/195
US Classification:
514564000, 514566000
Abstract:
A human having an erythropoietin resistant condition is treated by the administration of an iron chelator. The human can have end-stage renal disease, chronic renal disease, cancer or anemia. Administration of the iron chelator can essentially halt or diminish an erythropoietin resistant condition in a human.
Diagnosis And Treatment Of Human Kidney Diseases
US Patent:
7235542, Jun 26, 2007
Filed:
Apr 26, 2006
Appl. No.:
11/412237
Inventors:
Sudhir V. Shah - Little Rock AR, US
Assignee:
Shiva Biomedical, LLC - Little Rock AK
International Classification:
A01N 43/00, A01N 37/12
US Classification:
514183, 514564, 514 6
Abstract:
Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.
Diagnosis And Treatment Of Human Kidney Diseases
US Patent:
2007023, Oct 11, 2007
Filed:
Jun 12, 2007
Appl. No.:
11/808595
Inventors:
Sudhir Shah - Little Rock AR, US
International Classification:
A61K 31/44
US Classification:
514348000
Abstract:
Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content, in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.
Treatment Of Diabetic Nephropathy And Microalbuminuria
US Patent:
6267992, Jul 31, 2001
Filed:
Sep 21, 2000
Appl. No.:
9/666623
Inventors:
Hai-Ri Li - Mudanjiang, CN
Hyun Chul Lee - Seoul, CN
Mankil Jung - Seoul, CN
Sudhir V. Shah - Little Rock AR
Hyun Chul Lee - Seoul, CN
Mankil Jung - Seoul, CN
Sudhir V. Shah - Little Rock AR
Assignee:
Shiva Biomedical LLC - Paramus NJ
International Classification:
A61K 3578, A61K 3136
US Classification:
424725
Abstract:
Diabetic nephropathy and microalbuminuria are treated with the herb Salviae Miltiorrhizae Radix. In one embodiment, the method includes boiling the herb to form an aqueous extract. The aqueous extract is administered to the diabetic individual to treat diabetic nepliropathy or to an individual exhibiting microalbuminuria. Alternatively the method can include administering a salt of lithospermic acid extracted from the herb. The method can include determining the level of protein in urine before, during and/or after administering the aqueous extract or a salt of lithospermic acid.
Methods Of Diagnosing And Alleviating Gadolinium Toxicity
US Patent:
2008013, Jun 12, 2008
Filed:
Nov 28, 2007
Appl. No.:
11/987166
Inventors:
Sundararaman Swaminathan - Little Rock AR, US
Sudhir V. Shah - Little Rock AR, US
Sudhir V. Shah - Little Rock AR, US
Assignee:
CorMedix Inc. - Summit NJ
International Classification:
A61K 33/24, A61K 38/02, A61K 31/16, A61P 39/04, A61B 5/00
US Classification:
424617, 514 2, 514616, 600300, 128898
Abstract:
The present invention relates to novel methods of treating or reducing the likelihood of developing gadolinium toxicity by administering to a patient a metal chelator before, concurrently with, or after exposure to gadolinium. The novel methods comprise, inter alia, the use of iron chelators to aid patients at increased risk of developing a gadolinium-induced condition, such as nephrogenic systemic fibrosis, acute kidney injury, cardiovascular disease and accelerated senescence.
Calcium-Independent Phospholipase A.sub.2
US Patent:
5773276, Jun 30, 1998
Filed:
Oct 12, 1995
Appl. No.:
8/542071
Inventors:
Didier Portilla - Little Rock AR
Sudhir V. Shah - Little Rock AR
Sudhir V. Shah - Little Rock AR
Assignee:
Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
C12N 920
US Classification:
435198
Abstract:
The present invention provides a substantially pure phopholipase A. sub. 2 protein isolated and purified from rabbit kidney cortex, having a molecular weight of 28 kDa as determined by SDS-PAGE, is calcium independent, is cytosolic, has a specific activity of approximately 1. 2. mu. mol/mg protein/minute and a pH optimum of approximately 7. 5 and exhibits a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. Also provided are various methods of using, inhibiting or measuring.